Dualitas Therapeutics has secured $65 million in Series A funding to develop bispecific antibodies targeting two cell surface proteins on the same immune cell, leveraging proximity biology for enhanced immunology and inflammation treatments. Investors include Eli Lilly and Chugai Pharmaceutical. The Bay Area-based biotech aims to discover new target combinations to build next-generation immunomodulatory therapies with improved efficacy beyond conventional monoclonal antibodies.